SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?
Suresh Senan, MRCP, FRCR, PhDSurgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […] Read more
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial
Ricardo Sales dos Santos, MD, PhDIn Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more
The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?
Sibo Tian, MD+more
IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III […] Read more
Understanding the Promising Role of Stereotactic Ablative Radiotherapy in Treating Patients With Oligometastatic Disease
Arya Amini+more
The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […] Read more
Cardiac Radiation Dose, Cardiac Events, and Survival in Locally Advanced NSCLC
Megan DalyMegan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […] Read more
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain […] Read more
PCI Decreases the Risk of Brain Metastases in Patients with Locally Advanced NSCLC
By Elizabeth Gore, MD Posted: May 27, 2019 IN REFERENCE TO: De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell […] Read more
By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally […] Read more
2018 ASTRO Guideline for Palliative Thoracic Radiation Therapy for NSCLC: The Balance Between Curative and Palliative Radiotherapy
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous […] Read more
Living in the “Gray Zone”: Entering a New Age in Radiation Therapy for Patients with Lung Cancer
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection […] Read more